As the editor of MedCity News, I have given away a lot of business cards over the last 3 years. I have met entrepreneurs all over the country, learned about financing options from investors and talked with doctors about new ways of working with patients. I’ve listened to dozens of pitches and moderated panels about […]
Fundraising is one of the most challenging aspects in your role as an entrepreneur. There are a myriad of options available to finance your business and enable its growth from an initial idea through to a business success story. There is much to think about in choosing the right partner. In this blog, I address […]
It sucks to hear “no” and as an early stage investor, the law of numbers means I have to say it regularly. Sometimes I deliver it quickly, sometimes it’s after deliberation. But I try to always do it honestly with feedback because we can also be on the receiving end of a “no” and want the […]
I’m building a startup to help investors, acquirers, and service providers etc. connect with startups to do deals. Funding, M&A, customer acquisition–these aren’t new things, but before Mattermark existed these professionals were cooking up their own solutions to this problem, their own proprietary ways of gaining deal intelligence to grow their pipelines. Startups benefit from […]
Most of the startups we’ve backed at Homebrew don’t rush to announce their funding. Not because they’re all operating in stealth or pre-product – in fact some already are earning $1M+ in revenue per annum. They just don’t feel the need to draw attention to themselves or alert possible competitors. And my sense is the trend carries […]
Medtech IPOs have performed well in recent years, even outpacing other areas of the health industry, a top analyst said recently. The comments came as part of the MedTech Investing Conference in Minneapolis last week. Other industry executives at the conference also described a generally positive climate for medtech IPOs. In his presentation “Overview of […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
At a recent conference in Minneapolis, a panel discussing where the best medtech startup opportunities are located gave an answer sure to please the hometown crowd: the Midwest was singled out as a great location for starting new firms. “We love the Midwest,” said Jan Garfinkle, founder and managing director of Arboretum Ventures, a venture […]
There are more than 100,000 mobile health apps, by one research firm’s count, but the great majority of them get downloaded fewer than 50,000 times and don’t bring in more than $10,000 in revenue. Mobile research firm research2guidance surveyed more than 2,000 mobile health app developers around the world and examined the differences between those […]
Digital health is a popular business these days, but it’s also a tricky one. In theory, remote monitoring and engagement products have the potential to drive long-term cost savings, but robust data is lacking and consumer adoption so far has been relatively low. In a guest article for Re/code, Dr. Beth Seidenberg, former chief medical […]
Technologies that turn healthcare data into knowledge make up a market that’s projected to grow more than 20 percent over each of the next five years. It’s quickly become a crowded space with startups and big players alike, but according to Pamela Peele, there are still some pain points left to be solved. Peele is […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Which mobile health business models are companies having success with? One takeaway from the digital health panel at MidAmerica Healthcare Venture Forum is that everyone, from startups to big players, is still trying to figure that out, and it’s not a one-size-fits-all matter. Payment reform is just one of the factors still in flux that […]
A financial investor, two venture capitalists and a corporate venture investor had different perspectives but all agreed on one thing at the MidAmerica Healthcare Venture Forum on Tuesday – the importance of capital efficiency in companies they look at. “We’ve tried to be very careful about keeping the spend rate down,” said Bill Gantz, an […]
Dr. Akhil Saklecha has seen many a startup stumble over the process of getting physician adoption of new technology. If a company fails to get physicians on board early in the development process, it will ultimately fail to get the feedback needed to move toward second- and third-generation products and, finally, into mass production. But […]
Connecting patients with clinical trials that they’re eligible for, and keeping them engaged once they enroll, has sparked many a digital health company. And for good reason: Clinical trials cost pharmaceutical companies millions of dollars and get even more expensive and time-consuming when patients drop out. If you’re building a product that involves getting more […]
Digital health is finally coming of age. Young companies are making waves, but they’re also under more scrutiny by everyone from investors to the FDA. Healthcare experts and entrepreneurs will come together to discuss the challenges and opportunities in digital health and other sectors at the MidAmerica Healthcare Venture Forum, April 22-23 in Chicago. The […]
